Faes Farma, S.a. · BME:FAE
Faes Farma — H1 2024 Earnings Presentation
19 slides from Faes Farma's earnings presentation, July 2024
Slide 1: Business update H1 2024
Business update H1 2024 July 2024
Slide 2: Index
Index 1// 2// 3// Overview Business Results H1 2024 update H1 and outlook 2024
Slide 3: Overview H1 2024
Overview H1 2024 oF FAES FARMA
Slide 4: Highlights
Overview H1 2024 Highlights BUSINESS The positive trend from the start of the year continues in Q2, with revenue growth driven mainly by the PERFORMANCE good performance of Pharma in Spain and in international markets. FINANCIAL Solid cash generation now we enter the final phase of the industrial in
Slide 5: Key figures
Overview H1 2024 Key figures Total 273,6 M€ 78,5 M€ EBITDA* Income +8% +10% Income 111,7 M€ EBIT** 68,4 M€ top 3 +7% +10% molecules Total 58,3 M€ 157,9 M€ international NET profit 10% +11% income Rounded data *Operating profit before depreciation, amortisation and impairment ** Operating profit 5
Slide 6: Business update H1 2024
2// Business update H1 2024 6
Slide 7: Pharma portfolio continues to grow at a solid pace
Business Evolution H1 2024 Pharma portfolio continues to grow at a solid pace Total income by portfolio line Animal Nutrition and Pharma top 3 Health molecules H1 2024 H1 2023 % 9% 41% Pharma 247,6 226,6 9% Pharma top 3 molecules 111,7 104,1 7% Rest of Pharma 135,9 122,5 11% Animal Nutrition and Hea
Slide 8: Evolution top 3 molecules
Business Evolution H1 2024 Evolution top 3 molecules Positive performance in international markets (+6%). Slight growth in Spain (+1%) despite price BILASTINE 74,2 M€ reductions by the authorities (at the end of 2023). +5% Acceleration of sales growth driven by the performance in LATAM markets, espe
Slide 9: Overall positive developments in Pharma geographies
Business Evolution H1 2024 Overall positive developments in Pharma geografies Total income by business areas H1 2024 H1 2023 % Animal Nutrition and Health Pharma Pharma 247,6 226,6 9% 9% Spain Pharma Pharma Spain 92,9 85,5 9% 34% Licenses Pharma International (without licenses) 90,5 80,1 13% 24% Pha
Slide 10: Pharma Spain: Prescription sales leading the growth
Business update H1 2024 Pharma Spain: Prescription sales leading the growth INCOME PHARMA SPAIN Highlights H1 2024 H1 2024 H1 2023 %var PRESCRIPTION Spain Pharma 92,9 85,5 9% The positive evolution from the first quarter continues. Prescription 59,8 54,4 10% The respiratory franchise continued to gr
Slide 11: Pharma international (without licenses): new Middle East project
Business update H1 2024 Pharma international (without licenses). Continued good performance especially in the new Middle East project INCOME INTERNATIONAL (without licenses) H1 2024 H1 2023 %var International (withour licenses) 90,5 80,1 13% Highlights H1 2024 Subsidiaries LATAM 45,6 41,5 10% FAES L
Slide 12: Licenses. Continued growth trend in line with expectations
Business update H1 2024 Licenses. Continued growth trend in line with expectations Highlights H1 2024 INCOME LICENSES BILASTINE H1 2024 H1 2023 %var • A combination of projects maintaining a strong pace of growth (Asia Pacific +17%, Canada +27%) and other more mature areas Licenses 64,2 60,9 5% (Bra
Slide 13: Farm Faes. Sector challenges are improving
Business update H1 2024 Farm Faes. Sector challenges are improving INCOME FARM FAES Highlights H1 2024 H1 2024 H1 2023 %var • The decline in sales is slowing down and, Animal nutrition and health 26,0 26,4 -2% although still influenced by the lack of piglets due to emerging diseases, sales are recov
Slide 14: Results and outlook
= “URE RR au” 377 Results and outlook ms NRE Ae vc an
Slide 15: Double-digit profit growth ahead of expectations because of expense phasing
Results and outlook 2024 Double-digit profit growth ahead of expectations because of expense phasing H1 2024 H1 2023 Thousand € %change Ordinary income (sales) 261.151 236.205 10,6% Highlights H1 2024 Other operating income 12.510 16.804 -25,5% Tota Income 273.661 253.009 8,2% • Margin growth slight
Slide 16: Increased cash generation after reaching the final phase of industrial investments
Results and outlook 2024 Increased cash generation after reaching the final phase of industrial investments CASH FLOW Highlights H1 2024 2024 H1 Profit before tax 68.907 FINANCIAL SITUATION Positive financial situation and cash generation after the phase Depreciation and amortisation 10.074 of heavy
Slide 17: In 2024 we will continue to grow, driven by international expansion
Results and outlook 2024 In 2024, even with some major challenges on the horizon, we will continue to grow, especially driven by our international business expansion Guidance 2024 Impacts + 2024 Impacts - 2024 Other issues with an impact on the P&L • Double-digit growth in • Increase in personnel 20
Slide 18: Faes Farma - Caring for tomorrow, today
cl FAES FARMA Caring for tomorrow, today
Slide 19: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off